Doctor Negrín Hospital Reaches 100 Patients Treated With CAR-T Therapy

Since securing accreditation from the Ministry of Health in 2019, the facility has expanded its hematological service portfolio, recently launching second-line treatments for myelomas alongside its established CAR-T procedures.

• Milestone Reached: The Hospital Doctor Negrín has treated 100 patients with lymphomas and myelomas with CAR-T therapies since gaining accreditation in 2019.
• Cellular Mechanism: The protocol involves harvesting patient T-lymphocytes, genetically modifying them in a laboratory, and reinfusing them to target cancer cells.
• Expanded Access: The hematology department recently introduced second-line myeloma treatments, operating alongside established allogeneic hematopoietic progenitor (bone marrow) transplant protocols for related and unrelated donors.

Cellular Engineering and Clinical Indications

CAR-T cell therapy targets hematological malignancies through a cellular modification process. According to coverage by Canarias en Pleno, the treatment relies on extracting a patient’s T-lymphocytes from their bloodstream. These immune cells undergo genetic modification within a laboratory setting. Once reinfused via transfusion, the modified lymphocytes identify and attack cancer cells, activating the patient’s immune response against lymphomas and myelomas that previously resisted conventional treatments.

This advanced therapeutic framework demands synchronization across clinical specialties. The hospital’s data highlights the role of multidisciplinary committees combining specialists from Hematology, Hospital Pharmacy, Neurology, Intensive Care, and specialized nursing units. For patients requiring evaluation of complex hematologic disorders, consulting with [Hematologists] remains critical for accurate staging and treatment candidate selection.

Institutional Growth and Diagnostic Infrastructure

Reaching the 100-patient threshold establishes the facility as a reference center for advanced treatments for complex hematological pathologies within the Canary Islands. Beyond CAR-T administration, the medical center functions as a reference site for related hematopoiesis procedures, encompassing both related and unrelated allogeneic hematopoietic progenitor (bone marrow) transplants. These interventions are supported by diagnostic laboratories and ongoing clinical research and training initiatives coordinated by the hematology staff.

Operational logistics require continuous inter-hospital coordination. Oncologists and hematologists from across the Canary Islands participate in periodic multidisciplinary committee meetings hosted by the center to review new cases and update data on treated patients. Managing complex cellular therapies and post-infusion monitoring protocols involves collaboration with [Hospital Pharmacy].

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*